Olivier NATAF




A scientist by training, graduated in molecular biology from Pierre et Marie Curie University and from the University of Chicago also holds a MS in Pharmaco-Oncology from the École Normale supérieure, and a MS from École Supérieure de Commerce in Paris (ESCP) and a Master from The French Institute for International and Strategic Affairs (IRIS).
Before being appointed President France at the end of 2019, Olivier Nataf headed AstraZeneca's Oncology Business Unit in the United States, where he significantly contributed to developing this market. He also helped establish the collaborations with Merck, Innate Pharma and Daiichi- Sankyo for the entire Group.
In 2020, his commitment led him to join the Board of Directors of the LEEM and to become Chairman of the LEEM Cancer Committee. In addition, he also committed as Vice-President to the think tank Laboratoires Internationaux de Recherche (LIR).
His transversal vision but also his understanding of the patients’ route led him to committing in health innovation by inviting to a public-private collaboration. He contributed to the strong involvement of AstraZeneca to “L’Alliance Digitale Contre le COVID-19”. He is co-Founder of “Coalition Innovation Santé” alongside France Digitale, France Biotech and MedTech in France with the support of AP-HP, Bpifrance, EIT Health.
At the same time, his strong societal convictions led him to engage AstraZeneca as a social and civic actor: by the signature of an unprecedented partnership with L’Ascenceur (a collective of 20 associations working for equal opportunities) to support young people in their education, in their access to labour market, and in all activities for a greater social inclusion; through actions to reducing the company's carbon footprint through better control of the drug's life-cycle or, as part of the AZForest project, to act for reforestation operation in France.

Watch replays

CHAM 2020

Health industry: what autonomy for Europe?

Debate 26 September 2020, 09h00 - 10h00